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Introduction
============

For many common indications, palliative radiotherapy can be repeated to a previously irradiated target volume \[[@REF1]-[@REF4]\]. Such reirradiation often results in a clinical benefit, e.g., pain relief. In general, patients scheduled for radiotherapy have reported heightened levels of anxiety and/or depression \[[@REF5]-[@REF6]\], and current studies are looking at different interventions that might reduce these symptoms \[[@REF7]-[@REF8]\]. Relatively few studies have examined quality of life and patient-reported symptoms, including but not limited to anxiety and depression, before palliative reirradiation \[[@REF2],[@REF9]-[@REF10]\]. We hypothesized that patients scheduled for the reirradiation of a previously treated target volume might report reduced levels of anxiety and depression, as compared to patients receiving their first course of palliative radiotherapy, because they are familiar with the process of treatment planning and delivery, as well as the facility and staff they are going to meet. In order to test this hypothesis, a retrospective, single-institution study was performed, which employed previously collected questionnaires (Edmonton symptom assessment system, ESAS). This short, one-sheet questionnaire has been used by different radiotherapy departments and addresses major symptoms and wellbeing on a numeric scale of 0-10 (highest symptom severity 10), including anxiety and depression \[[@REF6],[@REF11]-[@REF13]\].

Materials and methods
=====================

The study included 102 unselected, consecutive patients at an academic teaching hospital, all of whom received palliative radiotherapy in routine clinical practice during the time period 2013-2015. Since 2013, the standard pre-treatment workup included symptom assessment with the ESAS tool, administered by a registered oncology nurse immediately before oncologist consultation and imaging for treatment planning, i.e., approximately one week before palliative radiotherapy. All medical records, except for inpatient psychiatric care, were available in the hospital's electronic patient record system. A statistical analysis was performed with IBM SPSS Statistics 24 (IBM, Armonk, NY, US). We analyzed two different subgroups, patients who were reirradiated to a previously treated target volume and those who received their first course of palliative radiotherapy. We employed the chi-square test (when appropriate, the Fisher exact probability test or t-test). A p-value ≤0.05 was considered statistically significant. Two-tailed tests were performed. Actuarial survival from start of radiotherapy was analyzed with the Kaplan-Meier method and log-rank test. Ethical approval was not required for this study in accordance with the national and institutional guidelines.

Results
=======

Thirty-eight of 102 patients (37%) received palliative reirradiation, mainly for bone metastases. Time from initial cancer diagnosis was significantly longer in the reirradiation group, while most other baseline characteristics, including age and performance status, were comparable to those of patients who received their first palliative radiotherapy (Table [1](#TAB1){ref-type="table"}).

###### Baseline characteristics before palliative radiotherapy

RT: radiotherapy, ECOG PS: Eastern Cooperative Oncology Group performance status

\* collapsed into four categories (prostate/breast/lung/other)

\*\* collapsed into four categories (bone/brain/lung/other)

  --------------------------------------------- ------------- ---- ----------- ---- ----------
  Characteristic                                No Reirrad.   \%   No 1. RT    \%   p-value
  Gender                                                                             
  Male                                          46            72   29          76    
  Female                                        18            28   9           24   0.65
  Primary tumor site                                                                 
  Prostate                                      16            25   15          39    
  Breast                                        6             9    6           16    
  Lung                                          20            31   8           21    
  Colorectal                                    3             5    2           5     
  Bladder                                       5             8    0           0     
  Malignant melanoma                            4             6    0           0     
  Others                                        10            16   7           18   0.23\*
  RT target type                                                                     
  Bone metastases                               34            53   32          84    
  Brain metastases                              9             14   2           5     
  Lymph node metastases                         2             3    0           0     
  Lung                                          10            16   2           5     
  Prostate or bladder                           7             11   1           3     
  Others                                        2             3    1           3    0.02\*\*
  RT fractionation                                                                   
  \>10 fractions                                12            19   9           24    
  10 fractions                                  31            48   10          26    
  5-9 fractions                                 17            27   13          34    
  \<5 fractions                                 4             6    6           16   0.15
  Systemic cancer treatment                                                          
  No                                            17            27   2           5     
  Within 4 wk. before RT                        30            47   23          61    
  More than 4 wk. before RT                     17            27   13          34   0.03
  Mean time from first cancer diagnosis to RT   42 months          72 months        0.009
  Mean ECOG PS                                  1.8                1.7              0.73
  Mean age                                      71 years           72 years         0.77
  --------------------------------------------- ------------- ---- ----------- ---- ----------

Mean anxiety and depression scores were not significantly different between the two groups, as illustrated in Table [2](#TAB2){ref-type="table"}.

###### Association between Edmonton symptom assessment system (ESAS) scores and radiotherapy setting

RT: radiotherapy

  ------------------- ------------------------------- ------------------------ ---------
                      Reirradiation Mean, SD, range   1\. RT Mean, SD, range    
  Parameter                                                                    p-value
  Anxiety             2.5 ± 2.7, 0-8                  2.7 ± 3.2, 0-10          0.71
  Depression          2.2 ± 2.4, 0-8                  2.1 ± 3.0, 0-10          0.86
  Pain (not moving)   3.7 ± 2.6, 0-8                  2.3 ± 2.5, 0-9           0.01
  Pain (moving)       5.3 ± 2.9, 0-9                  3.9 ± 3.2, 0-10          0.03
  Fatigue             4.7 ± 2.8, 0-9                  4.2 ± 3.0, 0-10          0.41
  Nausea              0.8 ± 1.3, 0-5                  1.4 ± 2.2, 0-8           0.18
  Appetite            3.4 ± 3.1, 0-10                 4.0 ± 3.4, 0-10          0.34
  Constipation        2.9 ± 3.3, 0-10                 2.3 ± 3.0, 0-10          0.36
  Dry mouth           2.5 ± 2.4, 0-8                  3.2 ± 3.0, 0-10          0.21
  Dyspnea             2.1 ± 2.5, 0-10                 3.0 ± 2.9, 0-10          0.11
  Sleep               2.6 ± 2.7, 0-8                  2.6 ± 2.8, 0-10          0.90
  Overall wellbeing   3.4 ± 2.3, 0-9                  3.7 ± 2.7, 0-10          0.56
  ------------------- ------------------------------- ------------------------ ---------

The same was true for the proportion of patients with symptom scores ≥4. Regarding anxiety, 38% of reirradiated and 31% of first-time-irradiated patients reported scores ≥4 (p = 0.52). Regarding depression, 29% of reirradiated and 25% of first-time-irradiated patients reported scores ≥4 (p = 0.82). Significant differences were seen for two ESAS items only, namely, the two pain-related items (Table [2](#TAB2){ref-type="table"}). 

An analysis limited to patients with bone metastases was also performed because of the significantly different numbers of patients with this treatment indication and the resulting higher pain scores in the reirradiated group. This analysis revealed insignificant differences in mean pain scores, anxiety, and depression between the reirradiation and the first irradiation groups (pain when not moving 3.9 vs. 2.9, pain when moving 5.5 vs. 5.1, anxiety 2.7 vs. 2.7, depression 2.5 vs. 2.8; all p\>0.15, respectively).

The actuarial median survival was 6.8 months for reirradiated and 5.5 months for first-time-irradiated patients, p=0.16. Identical proportions of short-term survivors (radiotherapy in the last 30 days of life) were recorded (11% each).

Discussion
==========

In the present study, the question "do patients who are scheduled to receive palliative radiotherapy report less anxiety and depression if they are to receive reirradiation\" was addressed. We hypothesized that previous experience and facing a known environment might be an advantage. However, the data failed to show any significant differences in anxiety and depression between reirradiated and first-time-irradiated patients. For the hypothesis to be true, several assumptions have to be met. For example, the previous experience with palliative radiotherapy must have been positive and the patient must be able to remember this experience. Our retrospective study was not able to shed light on these aspects because this information was not collected when the patients presented for treatment planning and scored their symptoms on the ESAS sheet. If the levels of anxiety and depression reflect worries about the prognosis, especially in patients with very limited survival expectation, radiation-related issues might be of lesser concern. Therefore, we analyzed short-term and median survival. No significant or clinically relevant differences between the two groups were found.

The data revealed imbalances regarding the proportion of patients with bone metastases and, probably as a consequence, pain scores before radiotherapy. More reirradiated patients had bone metastases and their pain scores were higher. In theory, pain might also interfere with anxiety and depression, even if previous studies showed no strong correlations \[[@REF11],[@REF13]-[@REF14]\]. To correct for this potential source of bias, we excluded patients treated for indications other than bone metastases. Also, in this analysis, similar anxiety and depression scores were found, despite comparable levels of pain. Even if we did not find other significant differences in baseline symptom severity and performance status, we cannot exclude the possibility that unmeasured imbalances in quality of life, the extent of disease, or socioeconomic factors might have overshadowed the impact of radiotherapy setting. Maybe, the presence of incurable cancer itself results in a certain burden of anxiety and depression, which is not very dependent on details of therapy. 

Since the patients were not selected for particular primary tumor types or treatment indications, the present study is probably representative of daily clinical practice in palliative radiotherapy facilities such as ours. Nevertheless, the following drawbacks must be taken into account. In retrospective studies, selection bias and incomplete recording of data, including, but not limited to, medications that are prescribed for anxiety or depression, or could cause these symptoms as side effects, might complicate the analyses and their interpretation. With a mean age of more than 70 years, our study group consisted of many elderly and geriatric patients. In addition, the study size was limited. If the present research question was to be addressed in a prospective study, it would have to include about 302 patients (assuming a mean ESAS value of 2.4 and a standard deviation of 3.1 in the first radiotherapy group (see Table [2](#TAB2){ref-type="table"}) and a mean of 1.4 in the reirradiated group; alpha 0.05, beta 0.2, power 0.8). Regarding study limitations, one also has to consider that we did not record the consequences of high symptom scores and their longitudinal changes during and after radiotherapy.

Anxiety was a relevant issue because 38% of reirradiated and 31% of first-time-irradiated patients reported scores ≥4. Regarding depression, 29% of reirradiated and 25% of first-time-irradiated patients reported scores ≥4. The recent ESAS study by Körner et al. reported scores ≥4 for anxiety in 38% and depression in 33% in a palliative radiotherapy setting \[[@REF6]\]. A previous study showed that younger patients were significantly more anxious than older patients and females reported more anxiety than males \[[@REF11]\]. Patients who reported higher feelings of nausea, tiredness, drowsiness, dyspnea, and worse appetite and overall well-being on the ESAS tool were more likely to report feelings of depression. Patients who reported higher nausea, drowsiness, and dyspnea and worse overall well-being more often reported higher feelings of anxiety. Without a doubt, ESAS is not the most comprehensive and advanced tool for the diagnosis of anxiety and depression \[[@REF14]-[@REF16]\], although it has often been used for the screening of symptoms before radiotherapy \[[@REF6],[@REF11]-[@REF13],[@REF17]-[@REF18]\]. It would be interesting to perform additional studies with other tools and more comprehensive questionnaires, and record concomitant medications and pre-existing conditions leading to higher scores.

Conclusions
===========

The facts that similar ESAS scores of anxiety and depression were observed and that the prognosis was comparable suggest that the magnitude of these symptoms might be associated with the presence of incurable cancer itself (or the related somatic symptom burden) rather than the setting in which palliative radiotherapy is performed.
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